Table 1. Animals included in the study.
For each animal we note the assigned number, cage number (to show independent housing and what animals were from Jackson or Charles River Laboratories), sex, genotype, experimental use, treatment (KA, Saline), dose (nL of KA or Saline), times of 24 h/day vEEG recording and anatomical assessment. The dose varied because pilot studies showed that doses between 70 and 100 nL all were successful in producing severe SE and there was no correlation between dose and the total number of chronic seizures (r = 0.01, p = 0.95). Therefore, doses were randomly assigned for this study.
| Subject ID | Cage ID | Sex | Genotype | Experimental use | Treatment | Dose (nL) | Times of EEG recording | Times of anatomical assessment |
|---|---|---|---|---|---|---|---|---|
| 1 | 75a-5 | Male | Cre +/− | EEG, Anatomy | KA | 100 | 2 wks, 10 wks | 12 wks |
| 2 | 76–1 | Female | Cre +/− | EEG, Anatomy | KA | 100 | 2 wks | 10 wks |
| 3 | 76–4 | Female | Cre −/− | EEG, Anatomy | KA | 100 | 2 wks, 10 wks | 12 wks |
| 4 | 77–2 | Female | Cre +/− | EEG, Anatomy | KA | 100 | 2 wks, 10 wks | 12 wks |
| 5 | 78–3 | Female | Cre −/− | EEG, Anatomy | KA | 70 | 10 wks | 12 wks |
| 6 | 78a-5 | Male | Cre −/− | EEG, Anatomy | KA | 80 | 2 wks, 10 wks | 12 wks |
| 7 | 80–4 | Female | Cre −/− | EEG, Anatomy | KA | 70 | 10 wks | 12 wks |
| 8 | 81–1 | Female | Cre −/− | EEG, Anatomy | KA | 70 | 10 wks | 12 wks |
| 9 | 99a-6 | Male | Cre −/− | EEG | KA | 100 | 10 wks | NA |
| 10 | Jack a-1 | Male | NA | EEG, Anatomy | KA | 80 | 2 wks, 10 wks | 12 wks |
| 11 | Jack a-2 | Male | NA | EEG, Anatomy | KA | 90 | 2 wks, 10 wks | 12 wks |
| 12 | CRL a-1 | Male | NA | EEG, Anatomy | KA | 70 | 2 wks, 10 wks | 12 wks |
| 13 | CRL a-2 | Male | NA | EEG, Anatomy | KA | 100 | 2 wks | 2 wks |
| 14 | 78a-6 | Male | Cre +/− | Anatomy | KA | 75 | NA | 3 wks |
| 15 | 79a-6 | Male | Cre −/− | Anatomy | KA | 70 | NA | 3 days |
| 16 | 82–1 | Female | Cre +/− | Anatomy | Saline | 100 | NA | 2 wks |
| 17 | 82–2 | Female | Cre +/− | Anatomy | Saline | 100 | NA | 2 wks |
| 18 | 82a-3 | Male | Cre −/− | Anatomy | Saline | 80 | NA | 3 days |
| 19 | 82a-4 | Male | Cre −/− | Anatomy | Saline | 100 | NA | 4 wks |
| 20 | 99–1 | Female | Cre −/− | EEG HFOs | Saline | 70 | 10 wks | NA |
| 21 | 99–3 | Female | Cre +/− | EEG HFOs | Saline | 100 | 10 wks | NA |
| 22 | 99a-5 | Male | Cre +/− | EEG HFOs | Saline | 70 | 10 wks | NA |
| 23 | 100–4 | Female | Cre −/− | EEG HFOs | Saline | 100 | 10 wks | NA |
| 24 | Jax a-3 | Male | NA | EEG HFOs | Saline | 100 | 2 wks | NA |
| 25 | Jax a-4 | Male | NA | EEG HFOs | Saline | 100 | 2 wks | NA |
Orange: IHKA animals; Blue: Saline-injected controls. NA: Not applicable. Jack: Mice from The Jackson Laboratory; CRL: Mice from Charles River Laboratories.